French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Thursday that Phase II data from its LANTIC trial evaluating corabotase for glabellar lines will be presented as a late-breaking session at the SCALE 2026 symposium on 16 May.

Corabotase has been recognized by the WHO and USAN as the first investigational molecule in a newly designated recombinant neuroinhibitor class.

The Phase I/II LANTIC trial is assessing the safety and efficacy of corabotase across three aesthetic indications involving moderate to severe upper facial lines: glabellar, forehead, and lateral canthal lines. Ipsen reported positive Phase II data in September 2025, citing a differentiated clinical profile in glabellar lines with rapid onset and sustained duration of effect.

Corabotase is currently being advanced through a broader Phase II and Phase III clinical development programme spanning multiple aesthetic and therapeutic indications. The investigational molecule, also known as IPN10200, was engineered using Ipsen's proprietary manufacturing platform to enhance receptor affinity, cellular uptake and resistance to degradation.

The ongoing LANTIC study includes 727 participants and compares varying doses of corabotase against placebo and Dysport across multiple trial stages. Ipsen expects additional proof-of-concept data later this year for forehead and lateral canthal lines indications.